Developing Diagnostic Tools for Challenging MGTS Cases
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
May 2025
January 2025
De Novo Sequencing a Bispecific T Cell Engager
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
November 2024
NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications